ClinicalTrials.gg
Not yet recruitingNCT06974084IMPACT-LCUpdated Jun 18, 2026

A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID

A Phase 2/3 interventional study of Maraviroc (MVC) and Atorvastatin, 10mg, 20mg, 40mg in Long COVID, sponsored by HealthBio, Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by HealthBio, Inc. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 194 studies in Post-Acute COVID-19 Syndrome with a site in United States — 62 open to participants now, 84 under way, 7 of them phase 3. Post-Acute COVID-19 Syndrome · United States.

Planned enrollment
24th of 155
252 · median 52
Started
2026
with 11 others
Phase 2/3
5 of 194
2 open now
Primary completion
2026-12
later than 31 of 83 live
Registered
168th of 194
by date

Among the 194 studies in Post-Acute COVID-19 Syndrome with a site in United States, this one is the 24th largest by planned enrollment of the 155 interventional ones that give a count, is one of 12 that started in 2026, is one of 5 in phase 2/3, reaches primary completion later than 31 of the 83 other live ones, and was the 168th registered.

Post-Acute COVID-19 Syndrome

605 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

62 of the 194 studies in Post-Acute COVID-19 Syndrome with a site in United States are open now. Recruiting first, the newest first:

57 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 145 Post-Acute COVID-19 Syndrome studies recruiting now, 70 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Post-Acute COVID-19 Syndrome with a site in United States, or all of them as a file.
02

Study summary

The IMPACT Long Covid Treatment clinical study (IMPACT-LC) is testing two repurposed and previously approved drugs, Maraviroc and Atorvastatin, for the treatment of non-hospitalized subjects with Long COVID. The main goals of the clinical study are to determine if this combination drug therapy can improve neurocognitive and physical functions in Long Covid patients, such as fatigue severity, heart rate, blood pressure, digestion, breathing, dizziness, and cognitive function. A secondary goal is to determine if biomarker levels, measured by a diagnostic test, can improve during treatment. To qualify for the trial, a subject must be an adult ≥ 18 and ≤ 65 years of age and meets the WHO-defined post-COVID-19 condition and has one or more new-onset Long Covid symptom that persist ≥ 3 months after the diagnosis of acute COVID-19 infection. A total of 252 participants will take either two daily doses of two existing medications (Maraviroc and Atorvastatin together as separate tablets) or a placebo (pills with no active ingredient) for 16 weeks. Although these medications are not yet approved for Long Covid, they are FDA-approved for use in treating other health conditions.

03

Conditions studied

  • Long COVID

Keywords

  • Long Covid
  • Post-COVID syndrome (PCS)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 and ≤ 65 years of age at the time of consent
  2. Meets WHO-defined post-COVID-19 condition (WHO definition: 'Post COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months. Common symptoms include fatigue, shortness of breath, cognitive dysfunction but also others and generally have an impact on everyday functioning. Symptoms may be new onset following initial recovery from an acute COVID-19 episode or persist from the initial illness. Symptoms may also fluctuate or relapse over time).
  3. One or more new onset symptoms that persisted for greater than 6 months after the diagnosis of acute COVID-19 infection. These symptoms include: cognitive impairment (brain fog), migraines, post-exertional malaise (PEM), myalgias, arthralgias, severe fatigue, tachyarrhythmias, postural orthostatic tachycardia syndrome (POTS), and shortness of breath. The previous COVID-19 infection should be documented in the form of a positive PCR laboratory test and/or medical records from a healthcare provider. The Long-COVID diagnosis should be documented in the medical records by a healthcare provider.
  4. Negative Lyme screen, as measured by the AcuDart test.
  5. Epstein-Barr Virus (EBV) DNA negative (centrally assessed).
  6. A long hauler index (LHI) of >0.71
  7. A PROMIS Fatigue 10a T-score score > 55
  8. Participants of should be surgically sterilized or or must agree to take effective measures during the study period. Adequate methods of birth control include: condoms, male or female, with or without a spermicide; diaphragm or cervical cap with spermicide; intrauterine device; any of the methods that require a prescription (such as contraceptive pills or path) or a male partner who has previously undergone vasectomy.
  9. Participant is willing and able to participate in the study and comply with all study requirements.
  10. Participant provided signed and dated IRB approved prior to initiation of any study procedures.
  11. Participant is able to read and understand English.

Exclusion criteria

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Participation in another therapeutic clinical trial in the past 2 months.
  2. History of allergy or anaphylaxis or allergic reaction to any component of atorvastatin and/or maraviroc.
  3. Uncontrolled hypothyroidism as defined as thyroid-stimulating hormone (TSH) and/or free thyroxine (FT4) values outside the local laboratory reference range at screening, or a change in thyroid hormone replacement dose within 6 weeks prior to screening.
  4. Pre-COVID history of conditions, migraines, neuropathy, inflammatory bowel disease (IBD), obsessive-compulsive disorder (OCD), or fatigue duration for ≥5 years, EBV infection, Lyme disease, fibromyalgia, arthritis, (COPD), chronic kidney disease (CKD G3a or greater), chronic heart failure (CHF), arrhythmias, bleeding disorders, and anticoagulation therapy.
  5. Presence of other conditions or differential diagnosis that better explains the symptoms of the patient than the suspected long COVID, in the opinion of the investigator.
  6. Hepatic impairment, defined as Score 7-9 (Class B) or greater.
  7. Active/acute infectious diseases like tuberculosis, infection (HIV), cytomegalovirus (CMV), (vector based) Lyme, EBV, virus (HBV), virus (HCV).
  8. Ongoing therapy, such as cyclosporine A (CsA).
  9. Use of statins within 6 months of randomization.
  10. Concomitant use of cyclosporine, gemfibrozil, tipranavir plus ritonavir, or glecaprevir plus pibrentasvir, or lipid-modifying doses (>1 gram/day) of niacin.
  11. :ALT ratio>1.5
  12. Elevations in IL-8 (>21 (pg/ml) and or IL-13 (>6.1 pg/ml) (centrally assessed with IncellKINE panel).
  13. Pregnant or breastfeeding
  14. History of substance use disorder (including alcohol use disorder or cannabis use disorder per criteria) within 3 months of enrollment, OR current hazardous alcohol use as defined by:

    • Self-reported consumption >14 drinks/week (males) or >7 drinks/week (females), OR
    • Binge drinking (≥5 drinks on one occasion for males, ≥4 for females) ≥1 time per week, OR
    • Clinical judgment that alcohol use would interfere with study compliance or safety
  15. Subjects with risk factors for myocardial ischemia/infarction, including but not limited to those with a prior history of MI, stroke, unstable angina,
  16. Any significant disease or disorder, which, in the opinion of the Investigator, may either put the participants at risk
  17. Azole antifungals (ketoconazole or itraconazole are not allowed) or macrolide antibiotics (clarithromycin is not allowed)
  18. History of use of maraviroc and/or atorvastatin for the off-label treatment of Long COVID.

    Prohibited concomitant medications

  19. Any statins within 6 months of randomization and between randomization and the participant's scheduled final visit
  20. Other systemically administered drugs with significant immunosuppressive activity, such as azathioprine, tacrolimus, cyclosporine, methotrexate, or cytotoxic chemotherapy between randomization and the participant's scheduled final visit
  21. Potent inhibitors (with or without a potent CYP3A inducer) including:

    1. clarithromycin
    2. cobicistat
    3. elvitegravir/ritonavir
    4. itraconazole
    5. ketoconazole
    6. nefazodone
    7. protease inhibitors (except tipranavir/ritonavir)
    8. telithromycin
  22. Drug Interactions that may Increase the Risk of Myopathy and Rhabdomyolysis:

    1. cyclosporine or gemfibrozil
    2. tipranavir plus ritonavir or glecaprevir plus pibrentasvir
    3. niacin (≥1 gram/day niacin)
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
252 participants (estimated)

Study arms

  • Active comparator
    Study Drug; Combination of Maraviroc (300mg) and Atorvastatin (10mg) given twice daily

    Subjects randomized to maraviroc/atorvastatin will receive maraviroc 300 mg and atorvastatin 10 mg twice daily oral for 16 weeks.

    Drug: Maraviroc (MVC) · Drug: Atorvastatin, 10mg, 20mg, 40mg

  • Placebo comparator
    Placebo of Maraviroc (300mg) and Atorvastatin (10mg) given twice daily

    Drug: Placebo, Maraviroc · Drug: Placebo, Atorvastatin

Interventions

  • Maraviroc, 300mg per tablet. Atorvastatin, 10mg per tablet

  • Atorvastatin, 10mg will be given twice daily oral along with Maraviroc, 300-mg

  • DrugPlacebo, Maraviroc

    Placebo of Maraviroc, 300mg

  • DrugPlacebo, Atorvastatin

    Placebo of Atorvastin, 10mg

06

What researchers measure

Primary outcomes

  1. Fatigue

    Fatigue will be measured via PROMIS Fatigue v1.0. The PROMIS Fatigue 10a assesses fatigue severity in the previous week. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The instrument translates the total raw score into a T-score with a mean of 50 and a standard deviation of 10. A score of 50 is the average for the United States general population (SD=10).

    Time frame: PROMIS Fatigue scores will be taken during screening (0-28 days before the first baseline) and at the EOT visit, week 12.

Secondary outcomes

  1. Improvement in dysautonomia symptoms as reflected by the Composite Autonomic Symptom Score (COMPASS-31)

    To assess the effect of the combination of maraviroc and atorvastatin, compared with placebo, on dysautonomia symptoms 12 weeks after treatment initiation in individuals with Long COVID.

    Time frame: Scores will be determined at Visit 1 (Day 1) and EOT (week -12)

  2. Improved Cognitive Function, measured by the PROMIS (Patient-Reported Outcomes Measurement Information System) Cognitive Function v.2.0 - Short Form 6a

    The PROMIS (Patient-Reported Outcomes Measurement Information System) Cognitive Function v.2.0 - Short Form 6a is a 6-item sub-set scale of the PROMIS Cognitive Function item bank that assesses patient-perceived cognitive deficits. Each item has five response options ranging in value from one to five. The total raw score for a short form with all questions answered, is the sum of the values of the response to each question and ranges between 6 and 30. The raw score is translated in a T-score, a standardized score with a mean of 50 and a standard deviation (SD) of 10.

    Time frame: Difference in T-score measured at Visit 1 (Day 1) and EOT (week-12)

  3. To assess if maraviroc and atorvastatin decrease the Long Hauler Index (LHI) from baseline to week 12.

    To assess the effect of the combination of maraviroc and atorvastatin, compared with placebo, on the LHI 12 weeks after treatment initiation in individuals with Long COVID.

    Time frame: LHI will be measured at Screening and EOT (week-12)

  4. To assess the proportion of participants with a PROMIS Fatigue T-score improvement from baseline ≥5 points 12 weeks after treatment initiation.

    In subjects with Long COVID complying with the key protocol criteria (evaluable participants) who received 12 weeks of study treatment: ● Change in the proportion of subjects who improve their PROMIS T-score from baseline to week 12 in maraviroc/atorvastatin and placebo groups.

    Time frame: From baseline Visit 1 (Day-1) and EOT (week-12)

  5. To determine the safety profile of maraviroc and atorvastatin in patients treated for Long COVID-19

    Participants report data will be compiled as follows: Percentage of participants reporting AEs from Dose 1 to 28 days after the last dose. Percentage of participants reporting SAEs from Dose 1 to 28 days after the last dose. Percentage of participants reporting AEs leading to discontinuation. Percentage of participants reporting SAEs leading to discontinuation.

    Time frame: Adverse event collection will be done during every Visit (Day-1, Week-4, Week-8, Week-12, Week-16 (EOT) and EOS (28-42 Days after last dose)

  6. To evaluate IncellKINE Biomarkers

    To assess the effect of the combination of maraviroc and atorvastatin, compared with placebo, on IncellKINE biomarker levels in individuals with Long COVID 12 weeks after treatment initiation.

    Time frame: Screening and EOT (week-12)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Dec 2026, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2025
First posted
May 15, 2025
StartEst.
Jul 15, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
May 2027
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06974084
Lead sponsor
HealthBio, Inc.
Collaborators
Lindus Health, Inc.
Responsible party
Sponsor
First posted
May 15, 2025
Start date
Jul 15, 2026 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Jun 18, 2026

Study contacts

Brad Fox
Contact
bradfoxaz@gmail.com
623-824-9165
Brian Brothen
Contact
brianb@incelldx.com
407-415-5891

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Maraviroc · Atorvastatin

Start the discussion